Cozad Asset Management Inc. acquired a new stake in AstraZeneca plc (NYSE:AZN) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 12,372 shares of the company’s stock, valued at approximately $434,000.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bessemer Group Inc. raised its stake in shares of AstraZeneca by 64.3% in the second quarter. Bessemer Group Inc. now owns 4,651 shares of the company’s stock valued at $163,000 after acquiring an additional 1,820 shares in the last quarter. FNY Investment Advisers LLC acquired a new stake in AstraZeneca in the second quarter valued at $175,000. Tiverton Asset Management LLC acquired a new stake in AstraZeneca in the second quarter valued at $178,000. Gilman Hill Asset Management LLC acquired a new stake in AstraZeneca in the second quarter valued at $205,000. Finally, Clarius Group LLC acquired a new stake in AstraZeneca in the second quarter valued at $213,000. Institutional investors and hedge funds own 15.99% of the company’s stock.
A number of analysts have weighed in on the company. ValuEngine upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research note on Saturday, July 28th. Zacks Investment Research upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Monday, July 16th. BMO Capital Markets restated a “buy” rating and issued a $41.00 price target on shares of AstraZeneca in a research note on Friday, May 25th. Morningstar restated a “hold” rating on shares of AstraZeneca in a research note on Tuesday, June 12th. Finally, Jefferies Financial Group cut AstraZeneca from a “buy” rating to a “hold” rating in a research note on Thursday, August 16th. Six analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $38.94.
AstraZeneca (NYSE:AZN) last issued its quarterly earnings data on Thursday, July 26th. The company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.38. The company had revenue of $5.16 billion for the quarter, compared to analyst estimates of $5.09 billion. AstraZeneca had a return on equity of 29.89% and a net margin of 11.98%. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.87 earnings per share. analysts anticipate that AstraZeneca plc will post 1.68 earnings per share for the current fiscal year.
The company also recently disclosed a semiannual dividend, which was paid on Monday, September 10th. Shareholders of record on Friday, August 10th were issued a dividend of $0.45 per share. This represents a dividend yield of 2.35%. The ex-dividend date of this dividend was Thursday, August 9th. AstraZeneca’s payout ratio is 20.56%.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: Book Value Per Share – BVPS
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.